基于网络药理学与分子对接技术探究木犀草素治疗宫颈癌的分子机制

Molecular mechanism of luteolin in treatment of cervical cancer based on network pharmacology and molecular docking technology

目的基于网络药理学与分子对接技术探讨木犀草素治疗宫颈癌的分子机制。方法运用中药系统药理学数据库与分析平台(TCMSP)对木犀草素进行类药性分析。分别在PharmMapper、Super-PRED和Swiss Target Prediction数据库中获取木犀草素作用靶点。运用GeneCards、OMIM和PharmGKB数据库获取宫颈癌相关靶点。通过EVenn获得木犀草素与宫颈癌的交集靶点,并使用Cytoscape3.8.1构建“木犀草素-交集靶点-宫颈癌”网络图。利用STRIING数据库对交集靶点进行蛋白质互作(PPI)网络分析,筛选核心靶点。采用David数据库对靶点进行基因本体论(GO)基因功能分析、京都基因和基因组百科全书(KEGG)信号通路富集分析。利用PyMoL 2.6.0、AutoDockTool 1.5.7和OpenBabel 2.4.1软件开展核心靶点与木犀草素的分子对接。将核心靶点在GEPIA数据库中进行生存分析及泛癌分析。结果获得木犀草素靶点449个、宫颈癌相关靶点1334个;木犀草素与宫颈癌交集靶点100个,其中核心靶点有24个,包括MMP2、HRAS、MAPK1、AKT1、RHOA和PGR等。GO和KEGG富集分析发现交集靶点参与生物过程455条,细胞组分70条,分子功能119条和143条KEGG信号通路。分子对接发现MMP2与木犀草素结合较好。宫颈癌患者生存曲线显示RHOA、MAPK1、MMP2和AKT1基因风险比率>1,HRAS和PGR的风险比率<1。泛癌分析显示HRAS和MAPK1在宫颈癌中高表达,并且HRAS有显著表达差异。结论木犀草素通过多靶点、多途径的作用方式治疗宫颈癌。

Objective To explore the molecular mechanism of luteolin in the treatment of cervical cancer based on network pharmacology and molecular docking technology.Methods The drug-like properties of luteolin were analyzed by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).The targets of luteolin were obtained from PharmMapper,Super-PRED,and Swiss Target Prediction databases.The targets related to cervical cancer were acquired from GeneCards,OMIM,and PharmGKB databases.The intersection targets of luteolin and cervical cancer were obtained through EVenn,and the"luteolin-intersection targets-cervical cancer"network diagram was constructed by Cytoscape 3.8.1.The STRING database was used to analyze the protein-protein interaction(PPI)network of intersection targets and screen the core targets.The Database for Annotation,Visualization and Integrated Discovery(David)was used to conduct Gene Ontology(GO)gene function analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)signaling pathway enrichment analysis of the targets.PyMoL 2.6.0,AutoDockTool 1.5.7 and OpenBabel 2.4.1 software were used to perform molecular docking between the core targets and luteolin.The survival analysis and pan-cancer analysis of the core targets were performed in the GEPIA database.Results A total of 449 targets of luteolin and 1334 targets related to cervical cancer were obtained;there were 100 intersection targets between luteolin and cervical cancer,of which 24 were core targets,including MMP2,HRAS,MAPK1,AKT1,RHOA and PGR.GO and KEGG enrichment analyses revealed that the intersection targets participated in 455 biological processes,70 cellular components,119 molecular functions,and 143 KEGG signaling pathways.Molecular docking revealed a good binding of MMP2 with luteolin.The survival curves of cervical cancer patients showed that the risk ratios of RHOA,MAPK1,MMP2 and AKT1 genes were greater than 1,while those of HRAS and PGR were less than 1.Pan-cancer analysis showed that HRAS and MAPK1 were highly expressed in cervical cancer,and HRAS had significant expression differences.Conclusion Luteolin treats cervical cancer through a multi-target and multi-pathway mechanism.